Elacestrant (Orserdu®): A Comprehensive Clinical and Regulatory Monograph on the First-in-Class Oral SERD for ESR1-Mutated ER+/HER2- Metastatic Breast Cancer

Executive Summary

[Elacestrant, marketed under the brand name Orserdu®, represents a significant therapeutic advance in the management of hormone-driven breast cancer. It is a first-in-class, orally bioavailable selective estrogen receptor degrader (SERD) that has secured regulatory approval for the treatment of postmenopausal women and adult men with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (][ESR1][)-mutated advanced or metastatic breast cancer that has progressed following at least one line of endocrine therapy.][1]

[The foundation of its approval rests on the pivotal Phase 3 EMERALD trial. This study demonstrated that Elacestrant conferred a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when compared directly against standard-of-care (SOC) endocrine monotherapy in its target patient population.][2][ The benefit was most pronounced in patients whose tumors retained a degree of endocrine sensitivity, as evidenced by a longer duration of benefit from prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.]

[This report provides a comprehensive analysis of Elacestrant, beginning with its unique pharmacological profile and dual mechanism of action that enables it to overcome acquired resistance driven by ][ESR1][ mutations. It critically examines the clinical evidence from the EMERALD trial, including key subgroup analyses that are essential for optimal patient selection. A detailed overview of the drug's safety, tolerability, and management of adverse events is presented, alongside a summary of its global regulatory journey with the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other health authorities.]

[The report concludes that Elacestrant has established a new standard of care for patients with ][ESR1][-mutated, ER+/HER2- metastatic breast cancer. Its approval has fundamentally altered clinical practice by cementing the role of liquid biopsy for real-time ][ESR1][ mutation testing as an essential, actionable diagnostic step. As a convenient oral agent, it offers a significant quality-of-life advantage over older, intramuscular therapies. The future role of Elacestrant is poised to expand through ongoing investigations into novel combination strategies and its potential application in earlier stages of breast cancer, heralding a new era in endocrine-based oncology treatment.]

Introduction and Pharmacological Profile

Overview of Elacestrant Hydrochloride

[Elacestrant hydrochloride, known during its development phase by the code RAD1901, is a novel, non-steroidal small molecule classified as an antineoplastic agent.][1][ It is marketed globally under the brand name Orserdu® by Stemline Therapeutics, Inc., a subsidiary of the Menarini Group.][3][ The therapy is formulated as oral film-coated tablets available in two strengths: 345 mg and 86 mg, to facilitate standard dosing and adjustments for toxicity or specific patient populations.][7][ While its primary development and approval are in the field of oncology, the compound was initially explored for its potential to alleviate vasomotor symptoms, such as hot flashes, in postmenopausal women, a testament to its potent interaction with the estrogen receptor pathway, before its profound anti-cancer properties became the central focus of its clinical development program.][2]

Mechanism of Action: A Novel Oral Selective Estrogen Receptor Degrader (SERD)

[Elacestrant is pharmacologically classified as an estrogen receptor antagonist and, more precisely, as a selective estrogen receptor degrader (SERD).][1][ Its mechanism of action is multifaceted. While it exhibits properties of a mixed ER agonist/antagonist depending on the dose, at the approved therapeutic dose of 345 mg daily, it functions as a pure and direct ER antagonist and a potent, selective downregulator of the estrogen receptor-alpha (ERα) protein.][2]

[The drug exerts its therapeutic effect through a dual mechanism. First, it competitively binds to the ligand-binding domain of ERα, physically blocking the binding of estrogen and thereby antagonizing the receptor's transcriptional activity. Second, and more critically for its role in resistant disease, the binding of Elacestrant induces a conformational change in the ERα protein, marking it for ubiquitination and subsequent degradation by the cellular proteasome.][3][ This active destruction of the receptor protein distinguishes SERDs from selective estrogen receptor modulators (SERMs) like tamoxifen, which primarily block the receptor, and aromatase inhibitors (AIs), which reduce systemic estrogen levels. By eliminating the ERα protein, Elacestrant effectively disrupts all downstream estrogen-mediated signaling, slows the translocation of any remaining receptors to the nucleus, and ultimately inhibits the proliferation of ER-dependent breast cancer cells.][6]

[This dual mechanism is fundamental to understanding Elacestrant's efficacy in the setting of acquired endocrine resistance. A primary mechanism by which ER+ breast cancers become resistant to first-line therapies, particularly AIs, is through the development of activating missense mutations in the ][ESR1][ gene. These mutations render the ERα protein constitutively active, meaning it can signal for cell growth and proliferation even in the absence of its estrogen ligand. Consequently, therapies that only aim to deplete estrogen (AIs) become ineffective. The first-generation SERD, fulvestrant, was developed to address this by both blocking and degrading the receptor. However, its clinical efficacy is hampered by poor pharmacokinetic properties resulting from its required intramuscular route of administration, which can lead to incomplete receptor degradation and allow for the eventual emergence of resistance.][11]

[Elacestrant's development as an orally bioavailable agent provides more consistent drug exposure and receptor occupancy.][6][ This allows for a more complete and sustained degradation of the ERα protein. In the context of an ][ESR1][ mutation, Elacestrant's mechanism does not just block a constitutively active receptor; it actively targets the driver of resistance for destruction.][6][ This explains its demonstrated efficacy in both preclinical models and the pivotal EMERALD clinical trial, where tumors harbored ][ESR1][ mutations and had become resistant to prior endocrine therapies, including both AIs and fulvestrant.][6][ Elacestrant is not merely a more convenient receptor blocker; it is a more effective eliminator of the molecular engine of resistance.]

Pharmacokinetics and Metabolism

[The clinical utility and management of Elacestrant are significantly influenced by its pharmacokinetic profile. The drug exhibits an oral bioavailability of approximately 10% to 11%.][2][ Following oral administration, it reaches steady-state plasma concentrations by day six of continuous dosing, with a mean accumulation ratio of approximately two-fold, indicating predictable accumulation with a once-daily regimen.][6][ Once in systemic circulation, Elacestrant is extensively bound to plasma proteins, with a binding fraction exceeding 99% that is independent of drug concentration.][6][ Its long elimination half-life, ranging from 30 to 50 hours, provides the pharmacological rationale for its convenient once-daily dosing schedule.][6]

[Elacestrant is cleared from the body primarily through hepatic metabolism. The process is dominated by the cytochrome P450 enzyme CYP3A4, with only minor contributions from CYP2A6 and CYP2C9.][2][ This heavy reliance on a single, major metabolic pathway is a critical clinical consideration. Drugs that are predominantly metabolized by one enzyme, especially one as common and susceptible to modulation as CYP3A4, are highly prone to significant drug-drug interactions (DDIs). This pharmacokinetic characteristic directly underlies the extensive warnings and detailed dose modification guidelines present in the official prescribing information. Clinicians are explicitly advised to avoid concomitant use of Elacestrant with strong or moderate inhibitors of CYP3A4 (e.g., certain azole antifungals, macrolide antibiotics, protease inhibitors) and inducers of CYP3A4 (e.g., rifampin, carbamazepine, St. John's Wort).][12][ This metabolic profile makes a thorough medication reconciliation, including over-the-counter supplements and specific foods like grapefruit, an absolute prerequisite for safe prescribing. It elevates the importance of the clinical pharmacist and comprehensive patient education in mitigating the risk of sub-therapeutic exposure or unexpected toxicity.]

[Following metabolism, the drug and its metabolites are eliminated predominantly via the feces, with approximately 82% of an administered dose recovered in feces (of which 34% is unchanged Elacestrant). A much smaller fraction, around 7.5%, is excreted in the urine, with less than 1% as the unchanged parent drug.][2]

Table 1: Key Characteristics of Elacestrant Hydrochloride

Characteristic	Description	Source(s)
Generic Name	Elacestrant hydrochloride	1
Brand Name	Orserdu®	1
Development Code	RAD1901	2
Drug Class	Antineoplastic Agent; Estrogen Receptor Antagonist; Selective Estrogen Receptor Degrader (SERD)	1
Mechanism of Action	Binds to estrogen receptor-alpha (ERα), blocking its transcriptional activity and inducing its proteasomal degradation.	6
Formulation	345 mg and 86 mg film-coated oral tablets	7
Oral Bioavailability	Approximately 10-11%	2
Primary Metabolism	Hepatic, primarily via Cytochrome P450 3A4 (CYP3A4)	2
Elimination Half-life	30 to 50 hours	6

Clinical Efficacy: The EMERALD Trial and Supporting Data

The Pivotal Phase 3 EMERALD Study (NCT03778931)

[The global regulatory approvals of Elacestrant were predicated on the robust findings from the EMERALD study, a landmark Phase 3 clinical trial.][2][ EMERALD was designed as a randomized, open-label, active-controlled, multicenter investigation to definitively assess the efficacy and safety of Elacestrant in a heavily pre-treated patient population. The trial enrolled a total of 478 participants, comprising postmenopausal women and adult men diagnosed with ER+/HER2- advanced or metastatic breast cancer.][4][ A key eligibility criterion was disease progression following one or two prior lines of endocrine therapy in the metastatic setting, with a mandatory requirement for all participants to have previously received a CDK4/6 inhibitor in combination with an endocrine agent.][4]

[Participants were randomized in a 1:1 ratio to one of two treatment arms. The investigational arm received Elacestrant at a dose of 345 mg orally once daily. The active control arm received the investigator's choice of a standard-of-care (SOC) endocrine monotherapy, which consisted of either fulvestrant (the existing standard SERD) or an approved aromatase inhibitor (letrozole, anastrozole, or exemestane).][4][ The randomization process was stratified by three key prognostic factors: ][ESR1][ mutation status (detected vs. not detected), history of prior treatment with fulvestrant, and the presence or absence of visceral metastases.][14]

Primary Efficacy Outcomes in the ESR1-Mutated Population

[The primary efficacy endpoint of the EMERALD trial was progression-free survival (PFS), as assessed by a blinded independent central review.][4][ While the trial evaluated the entire patient population, the regulatory approvals and the most compelling evidence of efficacy were derived from the pre-specified subgroup of patients whose tumors harbored a detectable ][ESR1][ mutation. This efficacy population consisted of 228 patients, representing 48% of the total trial cohort.][4]

[Within this ][ESR1][-mutated population, Elacestrant demonstrated a clear and statistically significant superiority over the SOC arm. The median PFS for patients treated with Elacestrant was 3.8 months, compared to just 1.9 months for those receiving fulvestrant or an aromatase inhibitor.][15][ This doubling of median PFS corresponded to a 45% reduction in the relative risk of disease progression or death, as indicated by a Hazard Ratio (HR) of 0.55 (95% Confidence Interval [CI]: 0.39 to 0.77), with a highly significant p-value of 0.0005.][5]

[In contrast, an exploratory analysis conducted in the subgroup of patients without a detectable ][ESR1][ mutation (the ][ESR1][ wild-type population) did not show a statistically significant benefit for Elacestrant. The HR for PFS in this group was 0.86 (95% CI: 0.63 to 1.19), indicating that the profound treatment effect observed in the overall trial population was primarily, if not exclusively, driven by the outcomes in the ][ESR1][-mutated cohort.][14][ This finding was instrumental in defining the specific, biomarker-driven indication for which Elacestrant was ultimately approved.]

Subgroup Analyses and Key Insights

[While the top-line PFS result of 3.8 months in the ][ESR1][-mutated population was statistically robust, a deeper, post-hoc analysis of the EMERALD data unveiled a more profound clinical insight. This analysis revealed that the duration of prior therapy with a CDK4/6 inhibitor served as a powerful predictive biomarker for the magnitude of benefit from Elacestrant.][17][ This finding is critical for identifying the patients most likely to achieve a durable response.]

[The analysis stratified patients by the length of time they had previously been treated with a CDK4/6 inhibitor in the metastatic setting. For patients with ][ESR1][ mutations who had received a prior CDK4/6i for 12 months or longer, treatment with Elacestrant resulted in a remarkable median PFS of 8.6 months. This stands in stark contrast to the 1.9-month median PFS observed in the corresponding SOC group, with a compelling HR of 0.41.][2][ This substantial benefit was consistently observed across various clinically relevant subgroups within this population, including those with challenging visceral metastases (liver and/or lung), bone-only disease, and those with co-occurring oncogenic mutations such as ][PIK3CA][.][20]

[This observation provides a crucial framework for understanding the biology of resistance and for optimizing patient selection. Progression on a CDK4/6i-based regimen can occur through different biological pathways. Some tumors may become completely independent of the estrogen receptor pathway, relying on alternative growth signals. Others may remain fundamentally dependent on ER signaling but develop a specific mechanism of endocrine resistance, such as an ][ESR1][ mutation. A longer duration of clinical benefit (e.g., ≥12 months) on a first-line CDK4/6i plus endocrine therapy strongly suggests that the patient's tumor remains "endocrine-sensitive" or "addicted" to the ER pathway for its survival and growth.]

[In such a patient, the emergence of an ][ESR1][ mutation is the specific mechanism that allows the tumor to escape the effects of the prior endocrine agent (typically an AI). For this patient, Elacestrant is not just another line of endocrine therapy; it is a precisely targeted agent that directly counteracts the newly acquired resistance mechanism in a tumor that is still highly vulnerable to effective ER blockade and degradation. This reframes Elacestrant's clinical value, transforming it from a drug with a modest average benefit across all ][ESR1][-mutated patients to a therapy with profound and durable efficacy in a clinically identifiable subgroup. It provides clinicians with a powerful tool for patient selection that goes beyond the mere presence of the ][ESR1][ mutation, incorporating the patient's prior treatment history as a surrogate marker for retained endocrine sensitivity.]

Table 2: Summary of Efficacy Results from the Phase 3 EMERALD Trial (ESR1-Mutated Population)

Endpoint	Elacestrant Arm (n=115)	Standard of Care Arm (n=113)	Key Statistic	Source(s)
Median Progression-Free Survival (PFS)	3.8 months	1.9 months	HR: 0.55 (95% CI: 0.39-0.77); p=0.0005	14
6-Month PFS Rate	~40%	~20%	-	18
12-Month PFS Rate	~26%	~8%	-	18
Subgroup: Prior CDK4/6i ≥12 months (Median PFS)	8.6 months	1.9 months	HR: 0.41 (95% CI: 0.26-0.63)	17

Comprehensive Safety and Tolerability Profile

Overview of Adverse Reactions

[The safety profile of Elacestrant has been well-characterized through the EMERALD trial and is generally considered manageable, with a toxicity profile consistent with other endocrine therapies. The most frequently reported adverse reactions (ARs), occurring in 10% or more of patients, are primarily gastrointestinal and musculoskeletal in nature. These include musculoskeletal pain (reported in 41% of patients), nausea (35%), fatigue (26%), and vomiting (19%).][8][ The majority of these events are of low severity, typically Grade 1 or 2, and can often be managed with supportive care.][17][ Notably, the incidence of nausea and vomiting can be significantly mitigated by instructing patients to take the medication with food, a recommendation that is explicitly included in the prescribing information.][8]

[In addition to clinical symptoms, certain laboratory abnormalities are commonly observed. The most notable are related to lipid metabolism and liver function. Increases in total cholesterol (30%) and triglycerides (27%) are frequent findings. Other common laboratory abnormalities include elevated aspartate aminotransferase (AST, 29%), elevated alanine aminotransferase (ALT, 17%), decreased hemoglobin (26%), and decreased sodium (16%).][8][ As with the clinical ARs, these laboratory changes are predominantly low-grade.]

Warnings and Precautions

[The prescribing information for Elacestrant includes specific warnings and precautions that require clinical attention and proactive monitoring.]

• Dyslipidemia:[ Hypercholesterolemia and hypertriglyceridemia are identified as a key warning. While these events were reported in 30% and 27% of patients, respectively, severe (Grade 3 or 4) elevations were infrequent, occurring in just 0.9% and 2.2% of patients.][3][ Nevertheless, the potential for these metabolic changes necessitates routine monitoring. It is recommended that a lipid profile be obtained prior to initiating Elacestrant and periodically throughout the course of treatment to detect and manage any significant elevations.][23]
• Embryo-Fetal Toxicity:[ Consistent with its potent mechanism of action involving the disruption of the estrogen receptor pathway, Elacestrant is expected to cause fetal harm if administered during pregnancy. Animal studies and the drug's pharmacology support this risk, making it a critical warning.][3][ The medication is contraindicated in pregnancy. Females of reproductive potential must be advised of this risk and are required to use effective contraception during treatment and for one week following the final dose. This recommendation extends to male patients with female partners of reproductive potential, who must also use effective contraception during the same timeframe.][8]

[While the overall safety profile is manageable, it does introduce specific monitoring requirements that distinguish it from some other endocrine therapies. For instance, AIs are primarily associated with musculoskeletal symptoms and bone density loss, while SERMs like tamoxifen carry a risk of thromboembolic events and endometrial changes. Elacestrant's profile, with its prominent warning for dyslipidemia, adds a metabolic monitoring component (i.e., routine lipid panels) to the patient's follow-up care. This, combined with the need for vigilant management of drug interactions, suggests a slightly higher burden of clinical management compared to older endocrine agents. It requires proactive monitoring and thorough patient counseling to ensure both safety and efficacy.]

Drug-Drug Interactions

[The most significant clinical risk associated with Elacestrant's pharmacology is its susceptibility to drug-drug interactions (DDIs), stemming from its primary metabolism by the CYP3A4 enzyme.]

• CYP3A4 Inhibitors:[ Co-administration of Elacestrant with strong or moderate inhibitors of CYP3A4 can lead to a substantial increase in Elacestrant plasma concentrations, thereby heightening the risk of toxicity. Therefore, concomitant use should be avoided whenever possible. If co-administration with a strong or moderate CYP3A4 inhibitor is medically necessary, a dose reduction of Elacestrant is mandated. The recommended dose is reduced to 172 mg once daily when used with a moderate inhibitor and to 86 mg once daily with a strong inhibitor.][12]
• CYP3A4 Inducers:[ Conversely, co-administration with strong or moderate inducers of CYP3A4 can significantly decrease Elacestrant plasma concentrations, potentially compromising its therapeutic efficacy. Concomitant use with these agents should also be avoided.][12]

Table 3: Common Adverse Reactions (≥10%) with Elacestrant in the EMERALD Trial

Adverse Reaction	Elacestrant Arm (All Grades %)	Elacestrant Arm (Grade 3-4 %)	SOC Arm (All Grades %)	SOC Arm (Grade 3-4 %)	Source(s)
Musculoskeletal Pain	41	7	39	1	8
Nausea	35	2.5	19	0.9	8
Increased Cholesterol	30	0.9	-	-	8
Increased AST	29	-	-	-	23
Increased Triglycerides	27	2.2	-	-	8
Fatigue	26	2	27	1	8
Decreased Hemoglobin	26	-	-	-	23
Vomiting	19	-	-	-	8
Increased ALT	17	-	-	-	23
Decreased Sodium	16	-	-	-	23
Decreased Appetite	15	0.8	10	0.4	8
Diarrhea	13	-	-	-	8
Headache	12	2	12	0	8

[Note: Data for SOC arm not available for all laboratory abnormalities in the provided sources.]

Dosing, Administration, and Special Populations

Recommended Dosing Regimen

[The standard recommended dosage of Elacestrant is 345 mg, administered orally once daily.][8][ A critical instruction for administration is that the medication must be taken with food. This practice is recommended to reduce the incidence and severity of gastrointestinal side effects, particularly nausea and vomiting.][8][ Patients should be counseled to swallow the tablets whole; they should not be chewed, crushed, or split, as this could alter the drug's absorption profile. It is also advised that patients not take any tablets that appear broken, cracked, or otherwise damaged.][8][ To maintain consistent plasma concentrations, the dose should be taken at approximately the same time each day. In the event of a missed dose, if it is remembered within 6 hours of the scheduled time, it can be taken. However, if more than 6 hours have passed, the missed dose should be skipped entirely, and the patient should resume the normal schedule the following day. Patients should not take an extra dose to make up for a missed one.][8]

Dosage Modifications

[To manage treatment-related toxicities, a clear, stepwise dose reduction schedule has been established. This provides clinicians with actionable guidance to maintain patients on therapy safely. The recommended dose modifications are as follows ][8][:]

• First Dose Reduction:[ 258 mg once daily (administered as three 86 mg tablets).]
• Second Dose Reduction:[ 172 mg once daily (administered as two 86 mg tablets).]

[If a patient requires a further dose reduction below 172 mg per day due to persistent or severe toxicity, Elacestrant should be permanently discontinued.]

Use in Special Populations

[Dosage adjustments are also required for specific patient populations, primarily those with impaired hepatic function.]

• Hepatic Impairment:[ Elacestrant is extensively metabolized by the liver, and its exposure is increased in patients with hepatic impairment.]
• Mild Impairment (Child-Pugh A):[ No dosage adjustment is necessary.]
• Moderate Impairment (Child-Pugh B):[ The dose should be reduced to 258 mg once daily.]
• Severe Impairment (Child-Pugh C):[ Elacestrant has not been studied in this population and should be avoided.][12]
• Renal Impairment:[ Based on available data, no dose adjustment is recommended for patients with mild to moderate renal impairment. However, data in patients with severe renal impairment are limited.][12]
• Lactation:[ It is not known whether Elacestrant is excreted in human milk. Due to the potential for serious adverse reactions in the breastfed infant, patients should be advised not to breastfeed during treatment and for one week after the final dose.][24]

Table 4: Dosage Modifications for Adverse Reactions and Hepatic Impairment

Condition	Recommended Dosage Modification	Source(s)
Adverse Reactions
Grade 1	Continue ORSERDU at current dose level.	26
Grade 2	Consider interruption until recovery to Grade ≤1 or baseline, then resume at the same dose level.	26
Grade 3	Interrupt until recovery to Grade ≤1 or baseline, then resume at the next lower dose level.	26
Grade 4	Permanently discontinue ORSERDU.	26
Hepatic Impairment
Mild (Child-Pugh A)	No dosage adjustment required.	8
Moderate (Child-Pugh B)	Reduce dosage to 258 mg once daily.	12
Severe (Child-Pugh C)	Avoid use.	12

Global Regulatory Status and Market Access

U.S. Food and Drug Administration (FDA)

[Elacestrant received regulatory approval from the U.S. FDA on January 27, 2023.][2][ In recognition of its potential to address a significant unmet medical need, the New Drug Application (NDA) submitted by Stemline Therapeutics was granted Priority Review status, which expedites the review process for drugs that may offer major advances in treatment.][3][ The approved indication is highly specific and biomarker-driven: for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ]ESR1-mutated[ advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.][1]

[A crucial component of this regulatory decision was the simultaneous approval of a companion diagnostic test. The FDA approved the Guardant360 CDx assay, a liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a blood sample, to identify patients with the requisite ][ESR1][ mutations who are eligible for treatment with Elacestrant.][14][ This parallel approval underscores the integral role of diagnostics in the era of precision oncology.]

European Medicines Agency (EMA)

[Following its success in the United States, Elacestrant also pursued marketing authorization in Europe. The European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for review in August 2022.][28][ The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval in July 2023, and the European Commission granted full marketing authorization on September 15, 2023.][7]

[The European indication is largely consistent with the FDA's but contains some nuances. It is approved for the treatment of postmenopausal women and men with ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ][ESR1][ mutation, who have experienced disease progression following at least one line of endocrine therapy that ]must include a CDK 4/6 inhibitor[.][7][ The inclusion of "locally advanced" disease and the specific requirement for prior CDK4/6i therapy reflect subtle differences in regulatory interpretation and clinical practice standards between the regions.]

Status in Other Jurisdictions (e.g., Australia)

[The process of securing reimbursement and market access is ongoing in other key regions. In Australia, for example, a submission for Elacestrant was received for consideration at the March 2025 meeting of the Pharmaceutical Benefits Advisory Committee (PBAC). This committee makes recommendations regarding the listing of medicines on the Pharmaceutical Benefits Scheme (PBS), which provides subsidized access for patients.][31]

[The regulatory pathway for Elacestrant highlights a critical trend in modern drug development: the rise of codependent technologies. The approval of Elacestrant is not for a drug in isolation, but for a therapeutic strategy that inextricably links the drug to a specific diagnostic test. The Australian submission exemplifies this, as it is a codependent application requesting simultaneous listing of the drug on the PBS and the associated ][ESR1][ genetic test on the Medicare Benefits Schedule (MBS).][32][ This creates a new layer of complexity for achieving market access. In healthcare systems where drug reimbursement (like the PBAC) and diagnostic test reimbursement (like the Medical Services Advisory Committee, or MSAC, in Australia) are managed by separate bodies with different evidentiary requirements and budget considerations, a delay or rejection in one process can effectively block patient access to the entire therapeutic strategy. This suggests that the global adoption of Elacestrant may not be uniform. Access will likely be fastest in integrated healthcare systems with streamlined processes for evaluating and reimbursing codependent technologies and potentially slower or more fragmented in systems that are not structured to handle this paradigm, leading to potential international disparities in access to this new standard of care.]

Place in Therapy and Clinical Practice Guidelines

Evolving Treatment Landscape for ER+/HER2- Breast Cancer

[The therapeutic landscape for ER+/HER2- metastatic breast cancer has been defined by sequential lines of endocrine therapy aimed at maximizing clinical benefit while delaying the need for more toxic chemotherapy. The established first-line standard of care is the combination of an endocrine agent (either an aromatase inhibitor or fulvestrant) with a CDK4/6 inhibitor.][20][ However, resistance to this combination is inevitable. One of the most common and well-characterized mechanisms of acquired resistance is the development of activating mutations in the ][ESR1][ gene, which are found in up to 40% of tumors after progression on an AI.][5]

[The presence of an ][ESR1][ mutation renders AIs ineffective, creating a significant unmet medical need for this large subset of patients. Elacestrant is precisely positioned to fill this gap. It is indicated as a monotherapy for use in the second- or third-line setting, specifically for patients with documented ][ESR1][ mutations who have progressed on a prior endocrine-based regimen, including a CDK4/6 inhibitor.][18]

Comparative Analysis: Elacestrant vs. Fulvestrant

[Prior to the approval of Elacestrant, the only available SERD was fulvestrant. The EMERALD trial provided a direct comparison of Elacestrant to a SOC arm in which the majority of patients received fulvestrant. In the key ][ESR1][-mutated population, Elacestrant demonstrated statistically superior PFS.][15][ Furthermore, preclinical studies suggest that Elacestrant may be a more potent SERD, retaining activity even in models with acquired resistance to fulvestrant, potentially due to its more favorable pharmacokinetic profile and ability to achieve higher, more sustained receptor occupancy.][11]

[Beyond efficacy, the most significant differentiator between the two agents is the route of administration and its impact on patient quality of life. Fulvestrant requires large-volume, often painful, intramuscular injections administered monthly in a clinical setting. Over time, this can lead to significant discomfort, injection site reactions, and scarring.][33][ Elacestrant, as a once-daily oral tablet, offers a profound improvement in convenience and patient experience, allowing for at-home administration and avoiding the physical burden of injections.][33]

Integration into Clinical Practice Guidelines (ASCO, NCCN, ESMO)

[The practice-changing data from the EMERALD trial led to rapid updates in major international oncology treatment guidelines. The approval of Elacestrant fundamentally altered the clinical relevance of ][ESR1][ mutation testing. Before Elacestrant, identifying an ][ESR1][ mutation was prognostically informative but did not typically alter the choice of the next line of therapy, which was often fulvestrant or chemotherapy regardless. The mutation explained ][why][ a patient had become resistant to an AI but did not point to a specific, superior treatment option.]

[The EMERALD trial forged a direct, actionable link: if an ][ESR1][ mutation is present, Elacestrant is superior to the previous standard of care.][2][ This evidence compelled a shift in clinical practice. The American Society of Clinical Oncology (ASCO) issued a "rapid recommendation update," a mechanism reserved for data deemed immediately practice-changing, advising routine testing for ][ESR1][ mutations at the time of progression on endocrine therapy.][36][ The National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) have also incorporated these recommendations into their guidelines.][37]

[Current guidelines from all three major bodies now recommend that patients with ER+/HER2- metastatic breast cancer undergo testing for ][ESR1][ mutations upon disease progression. Liquid biopsy (ctDNA analysis) is endorsed as the preferred method due to its convenience and ability to capture tumor heterogeneity.][36][ For patients who are found to have a detectable ][ESR1][ mutation, Elacestrant is now listed as a recommended treatment option.][23][ This swift and unanimous adoption into guidelines illustrates how a single successful targeted therapy can elevate a biomarker from being merely "nice to know" to an essential, "need to know" component of the standard of care, thereby reshaping the entire diagnostic and therapeutic algorithm for the disease.]

Future Directions and Ongoing Research

[The approval of Elacestrant as a monotherapy represents the first step in its integration into the oncology armamentarium. The future of the drug, and indeed the class of oral SERDs, lies in expanding its use through combination therapies and exploring its role in earlier stages of breast cancer.]

Combination Therapies: The ELEVATE and Other Trials

[A key strategy to overcome the complexity of tumor resistance is to target multiple signaling pathways simultaneously. Elacestrant is being actively investigated as a new, more potent, and more convenient endocrine "backbone" for combination with various targeted agents. The ELEVATE trial (NCT05563220) is a large, Phase 1b/2 umbrella study designed to assess the safety and efficacy of Elacestrant combined with several classes of targeted drugs. These include CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), an mTOR inhibitor (everolimus), a PI3K inhibitor (alpelisib), and an AKT inhibitor (capivasertib).][41][ The primary goal of these investigations is to develop effective, all-oral combination regimens that can further improve outcomes and delay the need for infused chemotherapy or antibody-drug conjugates.][41][ Other dedicated studies, such as the ADELA trial (NCT06382948), are focusing on specific promising combinations like Elacestrant plus everolimus.][45]

Exploration in Early-Stage and Other Settings

[Research is also expanding beyond the advanced/metastatic setting into earlier stages of the disease, where the goal is curative. The ELEGANT trial (NCT06492616) is a major, global Phase 3 study evaluating Elacestrant versus standard-of-care endocrine therapy in the adjuvant (post-surgical) setting for patients with high-risk, node-positive early-stage breast cancer.][46][ The hypothesis is that a more potent endocrine agent like Elacestrant may be more effective at preventing disease recurrence. Other studies are exploring its utility in specific populations, such as CDK4/6i-naïve metastatic patients (ELCIN trial, NCT05596409) and patients with challenging brain metastases.][34]

Unmet Needs and Concluding Remarks

[While the PFS data from EMERALD are compelling, long-term overall survival (OS) data are still maturing and will be important for fully defining the drug's impact. Encouragingly, early real-world evidence is beginning to emerge, suggesting that treatment outcomes in routine clinical practice may meet or even exceed those observed in the controlled setting of the clinical trial.][52]

[The success of Elacestrant has provided a crucial proof-of-concept for the entire therapeutic class of oral SERDs. For years, the development of these agents was fraught with challenges, and fulvestrant remained the only approved SERD, despite its limitations. Elacestrant's successful Phase 3 trial and subsequent global approvals have validated the therapeutic strategy and de-risked the development pathway for other oral SERDs currently in late-stage clinical trials.][33][ This is likely to usher in a new competitive landscape, which may lead to head-to-head trials, exploration of unique combination strategies for different agents, and potentially price competition. Ultimately, this innovation, sparked by the trailblazing success of Elacestrant, will benefit patients by providing more numerous and more effective endocrine treatment options for ER+ breast cancer.]

Table 5: Summary of Key Ongoing Clinical Trials for Elacestrant

Trial Name/Acronym	NCT Identifier	Phase	Patient Population/Setting	Intervention(s)	Primary Objective	Source(s)
ELEVATE	NCT05563220	1b/2	ER+/HER2- mBC, post-ET	Elacestrant + various targeted agents (alpelisib, everolimus, CDK4/6i, etc.)	Determine RP2D (Phase 1b) and evaluate PFS (Phase 2) of combinations	41
ELEGANT	NCT06492616	3	High-risk, node-positive, ER+/HER2- early BC, post 2-5 yrs of adjuvant ET	Elacestrant vs. SOC endocrine therapy (AI or tamoxifen)	Evaluate invasive breast cancer-free survival (IBCFS)	46
ELCIN	NCT05596409	2	ER+/HER2- mBC, CDK4/6i-naïve, post 1-2 lines of ET	Elacestrant monotherapy	Evaluate efficacy (PFS) and safety	49
ADELA	NCT06382948	3	ER+/HER2-, ESR1-mutated mBC, post ET and CDK4/6i	Elacestrant + everolimus vs. Elacestrant + placebo	Evaluate efficacy (PFS)	45
ELECTRA	NCT05386108	1b/2	ER+/HER2- mBC with brain metastases	Elacestrant monotherapy and in combination with abemaciclib	Evaluate safety and efficacy in patients with brain metastases	38

Conclusion

[Elacestrant (Orserdu®) has emerged as a transformative therapy in the field of oncology, specifically for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer harboring ][ESR1][ mutations. As the first orally bioavailable selective estrogen receptor degrader to gain regulatory approval, it addresses a critical unmet need for patients who have developed resistance to standard endocrine therapies.]

[Its approval, based on the robust efficacy data from the Phase 3 EMERALD trial, has not only provided a new, effective treatment option but has also fundamentally reshaped the clinical management paradigm. The trial's findings have elevated ][ESR1][ mutation testing from an informational biomarker to an essential, actionable diagnostic step, cementing the role of precision medicine and liquid biopsy in the routine care of this patient population. The significant improvement in progression-free survival, particularly in patients with retained endocrine sensitivity, underscores the drug's potent ability to counteract a key mechanism of acquired resistance.]

[With a manageable safety profile and the profound quality-of-life benefit of an oral versus an injectable formulation, Elacestrant has established a new standard of care. Ongoing research into novel combination therapies and its potential application in earlier disease settings promises to further expand its role. Elacestrant's successful development serves as a landmark achievement, validating the therapeutic potential of the oral SERD class and paving the way for a new generation of endocrine treatments that will continue to improve outcomes for patients with breast cancer.]

Works cited

1. Elacestrant: uses dosing, warnings, adverse events, interactions - Oncology News Central, accessed October 27, 2025, https://www.oncologynewscentral.com/drugs/monograph/185885-323010/elacestrant-oral
2. Pharmacology and Pharmacokinetics of Elacestrant - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10713198/
3. Orserdu (elacestrant) FDA Approval History - Drugs.com, accessed October 27, 2025, https://www.drugs.com/history/orserdu.html
4. Drug Trials Snapshots: ORSERDU | FDA, accessed October 27, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-orserdu
5. FDA Approves Orserdu for Metastatic, ER+ Breast Cancer, accessed October 27, 2025, https://www.breastcancer.org/research-news/orserdu-fda-approval
6. Elacestrant: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 27, 2025, https://go.drugbank.com/drugs/DB06374
7. EMA Recommends Granting a Marketing Authorisation for Elacestrant | ESMO, accessed October 27, 2025, https://www.esmo.org/oncology-news/ema-recommends-granting-a-marketing-authorisation-for-elacestrant
8. This label may not be the latest approved by FDA. For current ..., accessed October 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf
9. Elacestrant: MedlinePlus Drug Information, accessed October 27, 2025, https://medlineplus.gov/druginfo/meds/a623011.html
10. Elacestrant Dihydrochloride - NCI - National Cancer Institute, accessed October 27, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/elacestrant-dihydrochloride
11. Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer - PMC - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9709100/
12. Orserdu, INN-elacestrant, accessed October 27, 2025, https://ec.europa.eu/health/documents/community-register/2023/20230915161089/anx_161089_en.pdf
13. 217639Orig1s000 - accessdata.fda.gov, accessed October 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217639Orig1s000MultidisciplineR.pdf
14. FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated ... - OncLive, accessed October 27, 2025, https://www.onclive.com/view/fda-approves-elacestrant-for-er-her2-esr1-mutated-advanced-or-metastatic-breast-cancer
15. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, accessed October 27, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer
16. Orserdu | European Medicines Agency (EMA), accessed October 27, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu
17. US FDA approves ORSERDU™ (elacestrant) for ER+, HER2- advanced or metastatic breast cancer - Oncology Central, accessed October 27, 2025, https://www.oncology-central.com/us-fda-approves-orserdu-elacestrant-for-er-her2-advanced-or-metastatic-breast-cancer/
18. Elacestrant Secures a Place for ER+, HER2–, ESR1-Mutated Advanced/Metastatic Breast Cancer | OncLive, accessed October 27, 2025, https://www.onclive.com/view/elacestrant-secures-a-place-for-er-her2-esr1-mutated-advanced-metastatic-breast-cancer
19. European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer | OncLive, accessed October 27, 2025, https://www.onclive.com/view/european-commission-approves-elacestrant-for-pretreated-esr1-er-her2-breast-cancer
20. Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/
21. Elacestrant Shows Significant PFS Benefit in ESR1-Mutated Metastatic Breast Cancer, accessed October 27, 2025, https://www.ajmc.com/view/elacestrant-shows-significant-pfs-benefit-in-esr1-mutated-metastatic-breast-cancer
22. Elacestrant (oral route) - Side effects & dosage - Mayo Clinic, accessed October 27, 2025, https://www.mayoclinic.org/drugs-supplements/elacestrant-oral-route/description/drg-20544713
23. ESR1-mutated, ER+/HER2- mBC Treatment | ORSERDU® (elacestrant), accessed October 27, 2025, https://www.orserduhcp.com/
24. Dosing | ORSERDU™ (elacestrant), accessed October 27, 2025, http://w.orserdu.com/dosing/?EaHaN=h7LDHrMF6
25. ESR1-Mutated ER+/HER2 mBC Treatment - ORSERDU® (elacestrant), accessed October 27, 2025, https://www.orserdu.com/
26. ORSERDU® Daily Dosing & Modifications, accessed October 27, 2025, https://www.orserduhcp.com/dosing/
27. ORSERDU (elacestrant), FDA Approved for ER+/HER2- Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson, accessed October 27, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2023/orserdu-approved-er-her2-advanced-or-metastatic-breast-cancer/
28. EMA Accepts Marketing Authorization Application for Elacestrant in ER+/HER2- Advanced Breast Cancer | OncLive, accessed October 27, 2025, https://www.onclive.com/view/ema-accepts-marketing-authorization-application-for-elacestrant-in-er-her2--advanced-breast-cancer
29. Orserdu | European Medicines Agency - ClinPGx, accessed October 27, 2025, https://www.clinpgx.org/literature/15158462
30. Annotation of EMA Label for elacestrant and ESR1 - ClinPGx, accessed October 27, 2025, https://www.clinpgx.org/labelAnnotation/PA166339321
31. ELACESTRANT | Medicine Status Website - PBS, accessed October 27, 2025, https://www.pbs.gov.au/medicinestatus/document/1302.html
32. PICO Confirmation - Medical Services Advisory Committee, accessed October 27, 2025, https://www.msac.gov.au/sites/default/files/2024-10/1782_ratified_pico.pdf
33. Oral SERDs: Shifting the Outpatient Landscape of Metastatic Breast Cancer? | Oncology Nursing News, accessed October 27, 2025, https://www.oncnursingnews.com/view/oral-serds-shifting-the-outpatient-landscape-of-metastatic-breast-cancer-
34. Elacestrant in hormone receptor-positive metastatic breast cancer: a post-hoc analysis - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11847623/
35. Elacestrant and the Promise of Oral SERDs | Journal of Clinical Oncology, accessed October 27, 2025, https://ascopubs.org/doi/10.1200/JCO.22.00841
36. Guideline Update Provides New Testing and Treatment Recommendations for Patients With ER-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 Mutations - The ASCO Post, accessed October 27, 2025, https://ascopost.com/issues/june-25-2023/guideline-update-provides-new-testing-and-treatment-recommendations-for-patients-with-er-positive-her2-negative-metastatic-breast-cancer-with-esr1-mutations/
37. Oral Selective Estrogen Receptor Degraders (SERDs) for Metastatic Breast Cancer Treatment - Susan G. Komen®, accessed October 27, 2025, https://www.komen.org/breast-cancer/facts-statistics/research-studies/topics/elacestrant-orserdu-for-metastatic-breast-cancer-treatment/
38. Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11305773/
39. Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access? - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/39232441/
40. (PDF) Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access? - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/383734018_Elacestrant_in_ESR1-mutant_endocrine-responsive_metastatic_breast_cancer_should_health_authorities_consider_post_hoc_data_to_inform_priority_access
41. Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study. | Journal of Clinical Oncology - ASCO Publications, accessed October 27, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.1079
42. NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | ClinicalTrials.gov, accessed October 27, 2025, https://www.clinicaltrials.gov/study/NCT05563220
43. Elacestrant Combinations in Advanced Breast Cancer: A Phase 1b Safety and Efficacy Analysis - Conference Correspondent, accessed October 27, 2025, https://conference-correspondent.com/highlights/sabcs/sabcs-2024-breast-cancer/elacestrant-combinations-in-advanced-breast-cancer-a-phase-1b-safety-and-efficacy-analysis
44. Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study. - ASCO Meeting Program Guide, accessed October 27, 2025, https://meetings.asco.org/abstracts-presentations/233622
45. Study Details | NCT06382948 | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | ClinicalTrials.gov, accessed October 27, 2025, https://clinicaltrials.gov/study/NCT06382948
46. Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence - UCSF Clinical Trials, accessed October 27, 2025, https://clinicaltrials.ucsf.edu/trial/NCT06492616
47. NCT06492616 | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | ClinicalTrials.gov, accessed October 27, 2025, https://www.clinicaltrials.gov/study/NCT06492616
48. ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study. - ASCO, accessed October 27, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT495184
49. ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC)—An open-label multicenter phase 2 study. - ASCO Publications, accessed October 27, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS1127
50. Clinical Trials Using Elacestrant - NCI - National Cancer Institute, accessed October 27, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/elacestrant?pn=1
51. NCT05596409 | ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | ClinicalTrials.gov, accessed October 27, 2025, https://clinicaltrials.gov/study/NCT05596409
52. Fulvestrant and elacestrant utilization on prognostic outcome of patients with HR+ve/HER2-ve MBC. - ASCO Publications, accessed October 27, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e13094
53. Elacestrant Real-World Outcomes Exceed Expectations - Conference Correspondent, accessed October 27, 2025, https://conference-correspondent.com/highlights/sabcs/sabcs-2024-breast-cancer/elacestrant-real-world-outcomes-exceed-expectations
54. Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date - PMC - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10041978/